Join Growin Stock Community!

Sensei biotherapeutics, inc.SNSE.US Overview

US StockHealthcare
(No presentation for SNSE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNSE AI Insights

SNSE Overall Performance

SNSE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNSE Recent Performance

-4.79%

Sensei biotherapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SNSE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNSE Key Information

SNSE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNSE Profile

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Price of SNSE

SNSE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNSE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-19.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.67
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-19.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.67
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SNSE's latest earnings report released?

    The most recent financial report for Sensei biotherapeutics, inc. (SNSE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNSE's short-term business performance and financial health. For the latest updates on SNSE's earnings releases, visit this page regularly.

  • How much debt does SNSE have?

    As of the end of the reporting period, Sensei biotherapeutics, inc. (SNSE) had total debt of 2.02M, with a debt ratio of 0.07. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNSE have?

    At the end of the period, Sensei biotherapeutics, inc. (SNSE) held Total Cash and Cash Equivalents of 10.56M, accounting for 0.38 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SNSE's EPS continuing to grow?

    According to the past four quarterly reports, Sensei biotherapeutics, inc. (SNSE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.62. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SNSE?

    Sensei biotherapeutics, inc. (SNSE)'s Free Cash Flow (FCF) for the period is -3.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 34.44% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SNSE?

    The latest valuation data shows Sensei biotherapeutics, inc. (SNSE) has a Price-To-Earnings (PE) ratio of -0.42 and a Price/Earnings-To-Growth (PEG) ratio of 0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.